Categories
Change Password!
Reset Password!
Compared to standard triple therapy, nitazoxanide-based therapy effectively improves H. pylori elimination rates.
A novel systematic review and meta-analysis of randomized controlled trials suggests that nitazoxanide (NTZ)-based triple therapy may offer superior elimination rates for Helicobacter pylori (H. pylori) when compared to conventional standard triple therapy, amid rising global antibiotic resistance.
H. pylori disease remains a pivotal cause of chronic gastritis, peptic ulcer disease, and gastric carcinoma, impacting nearly half of the world’s population. However, declining efficiency of standard regimens—largely driven by resistance to clarithromycin and metronidazole—has created an urgent need for alternative therapeutic strategies. NTZ, a broad-spectrum antimicrobial agent, has emerged as a potential candidate owing to its unique mechanism and low resistance profile.
The analysis pooled data from 8 randomized controlled trials involving 1,286 patients, comparing NTZ-based triple therapy with standard triple therapy. A random-effects model was utilized for calculating pooled risk ratios (RRs) with 95% confidence intervals (CIs). NTZ-based regimens delivered consistently superior eradication rates across both controlled and real-world analyses, with sustained post-treatment efficacy (Table 1).
While NTZ-based regimens showed a favorable trend in symptom control, reductions in abdominal pain (RR = 0.50) and nausea (RR = 0.78) were not statistically significant. The risk of bias across included studies ranged from low to high. Overall certainty of evidence remained high. Egger’s test indicated no significant publication bias (P = 0.161). Thus, the superior eradication rates observed with NTZ-based therapy suggest it could serve as a promising alternative in the era of antibiotic resistance, particularly where standard triple therapy is failing.
Journal of Clinical Gastroenterology
Comparative Efficacy and Safety of Nitazoxanide-based Triple Therapy Versus Standard Triple Therapy in Treating Helicobacter Pylori Infections An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials
Syed Hassan Ali et al.
Comments (1)